NovoCure Limited
NVCR
$15.21
$3.2827.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 174.35M | 167.20M | 158.81M | 154.99M | 161.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.35M | 167.20M | 158.81M | 154.99M | 161.27M |
| Cost of Revenue | 40.45M | 44.73M | 41.47M | 38.52M | 32.46M |
| Gross Profit | 133.90M | 122.48M | 117.33M | 116.47M | 128.81M |
| SG&A Expenses | 110.18M | 104.47M | 101.02M | 100.56M | 138.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.53M | 203.23M | 198.33M | 192.86M | 221.61M |
| Operating Income | -37.18M | -36.02M | -39.52M | -37.87M | -60.35M |
| Income Before Tax | -40.95M | -30.02M | -34.98M | -30.30M | -55.21M |
| Income Tax Expenses | -16.46M | 7.25M | 5.16M | 4.02M | 10.72M |
| Earnings from Continuing Operations | -24.50M | -37.27M | -40.14M | -34.32M | -65.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.50M | -37.27M | -40.14M | -34.32M | -65.92M |
| EBIT | -37.18M | -36.02M | -39.52M | -37.87M | -60.35M |
| EBITDA | -34.48M | -32.36M | -36.08M | -34.54M | -58.61M |
| EPS Basic | -0.22 | -0.33 | -0.36 | -0.31 | -0.61 |
| Normalized Basic EPS | -0.36 | -0.17 | -0.20 | -0.17 | -0.46 |
| EPS Diluted | -0.22 | -0.33 | -0.36 | -0.31 | -0.61 |
| Normalized Diluted EPS | -0.36 | -0.17 | -0.20 | -0.17 | -0.46 |
| Average Basic Shares Outstanding | 112.24M | 111.91M | 111.57M | 110.28M | 108.47M |
| Average Diluted Shares Outstanding | 112.24M | 111.91M | 111.57M | 110.28M | 108.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |